Related references
Note: Only part of the references are listed.Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action
Stephen J. Gardell et al.
MOLECULAR PHARMACOLOGY (2007)
Modulation of NR2B-regulated contextual fear in the hippocampus by the tissue plasminogen activator system
Erin H. Norris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease
Joo-Yong Lee et al.
NEUROSCIENCE LETTERS (2007)
Purkinje neuron degeneration in nervous (nr) mutant mice is mediated by a metabolic pathway involving excess tissue plasminogen activator
Jianxue Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
JS Jacobsen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus
R Pawlak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Acute γ-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease
TA Comery et al.
JOURNAL OF NEUROSCIENCE (2005)
Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis
JK Hennan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Elevated amyloid β protein (Aβ42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene
N Ertekin-Taner et al.
HUMAN MOLECULAR GENETICS (2005)
Pain: Moving from symptom control toward mechanism-specific pharmacologic management
CJ Woolf
ANNALS OF INTERNAL MEDICINE (2004)
Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice
HM Tucker et al.
NEUROSCIENCE LETTERS (2004)
Plasminogen activator inhibitor-1
A Gils et al.
CURRENT MEDICINAL CHEMISTRY (2004)
Plasmin Deficiency in Alzheimer's Disease Brains: Causal or Casual?
Carlos G. Dotti et al.
NEURODEGENERATIVE DISEASES (2004)
WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation
DL Crandall et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Amyloid β-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells
J Davis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease
Y Ling et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2003)
Peptidases, proteases and amyloid beta-peptide catabolism
LB Hersh
CURRENT PHARMACEUTICAL DESIGN (2003)
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
DM Walsh et al.
NATURE (2002)
Plasmin cleaves Aβ42 in vitro and prevents its aggregation into β-pleated sheet structures
C Exley et al.
NEUROREPORT (2001)
Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues
H Hino et al.
NEUROSCIENCE LETTERS (2001)
Tissue plasminogen activator requires plasminogen to modulate amyloid-β neurotoxicity and deposition
HM Tucker et al.
JOURNAL OF NEUROCHEMISTRY (2000)
Share Paper
